Holen Sie sich die Stockscreener-App
0.00
20.52%
-0.0268
Handel nachbörslich:
.01
0.01
+
Viracta Therapeutics Inc Aktie (VIRX) Neueste Nachrichten
Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Up 76.5% in July - Defense World
Comparing Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
Viracta Therapeutics Announces Wind Down Of Operations - MarketScreener
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Fierce Biotech Layoff Tracker 2025: Relay sheds staff again; Sail lays off employees - Fierce Biotech
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Viracta Therapeutics (VIRX) to Release Quarterly Earnings on Thursday - Defense World
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - insights.citeline.com
Calif. biotech company once worth $400M lays off every remaining employee - SFGATE
Viracta Therapeutics Terminates Employees & Winds Down Operations - Contract Pharma
Viracta Winds Down Business, Unable to Weather Financial Troubles - BioSpace
Viracta Therapeutics Announces Wind Down of Operations - GlobeNewswire
VIRX stock plunges to 52-week low, touches $0.08 - MSN
Viracta Therapeutics strikes deal to avoid default - Investing.com
Viracta Therapeutics faces Nasdaq delisting over audit issue By Investing.com - Investing.com Canada
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - insights.citeline.com
North American Morning Briefing : Boeing Stock -2- -December 30, 2024 at 07:00 am EST - MarketScreener
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure - Yahoo Finance
Viracta Therapeutics, Inc. Initiates Strategic Alternatives Review and Closes NAVAL-1 Trial for EBV+ Lymphomas - Nasdaq
Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com
Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Viracta Therapeutics faces Nasdaq delisting risk - Investing.com
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization - BioSpace
Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com UK
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Viracta reports progress in PTCL treatment trial - Investing.com
How a well-traveled brain cancer drug turned into an $8 million payday for an East Bay firm - The Business Journals
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher - GlobeNewswire
Viracta Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - Yahoo Finance
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck - InvestorPlace
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - Yahoo Finance
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan - Yahoo Finance
Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight - GlobeNewswire
Viracta Therapeutics reports Q3 results, clinical trial progress By Investing.com - Investing.com Canada
Epstein-Barr Virus Market Likely to Exhibit Substantial - GlobeNewswire
Viracta Therapeutics, Inc.(NasdaqGS: VIRX) dropped from S&P Global BMI Index - MarketScreener
Viracta Therapeutics to Host R&D Day on October 4, 2023 - GlobeNewswire
Viracta demonstrates promising and durable signal of EBV+ drug candidate - Clinical Trials Arena
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma - Yahoo Finance
Viracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next Stage - Benzinga
2 “Strong Buy” Penny Stocks With Over 400% Upside on the Horizon - Yahoo Finance
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference - GlobeNewswire
Viracta Nana-val gets orphan drug status in EU for blood cancer subtype - Seeking Alpha
Peripheral T-cell Lymphoma Pipeline Insight Report: 38+ Emerging Therapies and Treatment Outlook | DelveInsight - Yahoo Finance
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth - PR Newswire
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma - Nasdaq
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases - PR Newswire
4 Small Stocks to Bet on in an Upbeat Drugs Industry - Zacks Investment Research
Viracta Therapeutics to Present at the Jefferies Healthcare Conference - Seeking Alpha
Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors - MarketScreener
BioSpace Movers & Shakers, Feb. 18 - BioSpace
Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference - BioSpace
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors - MarketScreener
Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference - MarketScreener
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction - PR Newswire
VIRXViracta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team - Stock Titan
Viracta Therapeutics (VIRX) - Zacks Investment Research
Viracta Therapeutics (VIRX) Earnings Date and Reports 2025 - MarketBeat
Viracta Therapeutics (VIRX) Stock Price, News & Analysis - MarketBeat
Viracta Therapeutics Stock Price, Quotes and Forecasts | OTC:VIRX - Benzinga
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement - PR Newswire
1.96%
1.11%
Kapitalisierung:
|
Volumen (24h):